



Annual Report 2007

In Detail



DOCKET
A L A R M

Find authenticated court documents without watermarks at docketalarm.com.

Content

01	Marketed Products	04
	Summary of Achievements	05
	Tracleer®	06
	Ventavis®	08
	Zavesca®	08
02	Research & Development	10
	Drug Discovery	11
	Drug Discovery Platforms	11
	Therapeutic Areas	12
	Clinical Development	18
03	Our Strategy	27
04	Business Development	29
05	Financial Report	32
	Corporate Governance	37
	Consolidated Financial Statements	49
	Holding Company Statements	78

01

Marketed Products

Summary of achievements

Actelion continued its strong performance in 2007 and further built its leadership position in pulmonary arterial hypertension (PAH) with Tracleer® (bosentan) sales of CHF 1,18 billion, a growth of 31% compared to the previous year (+32% in local currencies). This strong performance was seen in all regions worldwide, including the United States, Europe, and Japan in particular. It was also the first full year of marketing Ventavis® (iloprost) after the acquisition of CoTherix in the United States. In an increasingly competitive PAH market, Ventavis® was able to contribute CHF 78.2 million to our PAH franchise revenues.

These excellent results are particularly remarkable considering that new competition entered the market in 2007 within the class of endothelin receptor antagonists (sitaxentan in the European Union and ambrisentan in the United States). Actelion's in-depth knowledge of the PAH market, together with our highly professional and determined worldwide marketing and sales force, continued medical education activities, and further geographical expansion, were the basis for maintaining leadership and further growth.

Actelion further strengthened the profile of its flagship brand, Tracleer®. In 2007, we submitted an application in the US and Europe to expand the indication of Tracleer® for patients with PAH in WHO Functional Class II* (FC II), based on the conclusive results of the EARLY study – the only study investigating the effects of a PAH therapy specifically in a FC II patient group. With EARLY, Tracleer® has shown a significant effect on delaying time to clinical worsening, a measure of disease progression, in three separate randomized controlled trials.

The positive results of the double-blind, placebo-controlled, multi-national BENEFIT trial – which investigated the effects of Tracleer® in a patient population outside of WHO group I*, namely patients with chronic thromboembolic pulmonary hypertension (CTEPH) – further proved the value of Tracleer® for patients. In June 2007, the EMEA granted approval in the European Union for an expansion of the indication of Tracleer® for reducing the number of new digital ulcers in patients suffering from systemic sclerosis and ongoing digital ulcer disease. Digital ulcers are a serious and very debilitating consequence of this disease.

* WHO clinical classification of pulmonary hypertension group diseases sharing similarities. PAH is WHO group 1. Group 1 comprises the following classifications:

- I. Patients with pulmonary hypertension in whom there is no limitation of usual physical activity
- II. Patients with pulmonary hypertension who have mild limitation of physical activity
- III. Patients with pulmonary hypertension who have a marked limitation of physical activity
- IV. Patients with pulmonary hypertension who are unable to perform any physical activity at rest and who may have signs of right ventricular failure.

Actelion's strong commitment to expand Tracleer® into new indications is demonstrated by the comprehensive clinical trial program, including the COMPASS trials (combination therapy), BUILD 3 (idiopathic pulmonary fibrosis) and FUTURE (pediatric indication).

Several marketing and life cycle activities were initiated for Ventavis® in 2007 to enhance its profile and set it up for continued success in 2008.

Zavesca® (miglustat), Actelion's second global brand, generated sales of CHF 35.3 million, a growth of 39% compared to the previous year. Increased awareness and acceptance of the value of Zavesca® for patients suffering from Type 1 Gaucher disease are the basis for future market share growth. New data published in 2007 confirmed the positive effects of Zavesca® on Gaucher disease related bone manifestations, and bone pain in particular, strengthening the competitive profile of the brand.

The submission for an expansion of the indication to patients suffering from Niemann-Pick Type C disease is still under review by the European regulatory authorities.

Actelion currently markets the following products:

Product	Indication(s)	Status	Commercialization rights
Tracleer®	Pulmonary arterial hypertension	marketed	Actelion
	Prevention of digital ulcers in patients with systemic sclerosis	registered ⁽¹⁾	Actelion
	Prevention of digital ulcers in patients with systemic sclerosis	in registration ⁽²⁾	Actelion
Ventavis®	Pulmonary arterial hypertension	marketed	Actelion ⁽³⁾
Zavesca®	Type 1 Gaucher disease	marketed	Actelion ⁽⁴⁾

(1) Only in the EU

(2) A product is said to be "in registration" when it has completed Phase III clinical trials and its developer is in discussion with the relevant regulatory authorities relating to the filing of a new drug application for the product.

(3) Only in the USA.

(4) Except Israel, the West Bank and Gaza Strip.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.